Article Text

This article has a correction. Please see:

PDF
Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis
  1. K D Hadfield1,
  2. W G Newman1,
  3. N L Bowers1,
  4. A Wallace1,
  5. C Bolger2,
  6. A Colley3,
  7. E McCann4,
  8. D Trump1,
  9. T Prescott5,
  10. D G R Evans1
  1. 1
    Academic Unit of Medical Genetics, University of Manchester and Regional Genetics Service, Manchester, UK
  2. 2
    National Centre for Neurosurgery, Dublin, Republic of Ireland
  3. 3
    Department of Clinical Genetics, Liverpool Hospital, Sydney, Australia
  4. 4
    Department of Clinical Genetics, Glan Clwyd Hospital, Rhyl, Denbighshire, UK
  5. 5
    Department of Medical Genetics, Rikshospitalet University Medical Centre, Oslo, Norway
  1. Professor G Evans, Department of Clinical Genetics, St Mary’s Hospital, Hathersage Road, Manchester M13 0JH, UK; gareth.evans{at}cmmc.nhs.uk

Abstract

Background: Schwannomatosis is a rare condition characterised by multiple schwannomas and lack of involvement of the vestibular nerve. A recent report identified bi-allelic mutations in the SMARCB1/INI1 gene in a single family with schwannomatosis. We aimed to establish the contribution of the SMARCB1 and the NF2 genes to sporadic and familial schwannomatosis in our cohort.

Methods: We performed DNA sequence and dosage analysis of SMARCB1 and NF2 in 28 sporadic cases and 15 families with schwannomatosis.

Results: We identified germline mutations in SMARCB1 in 5 of 15 (33.3%) families with schwannomatosis and 2 of 28 (7.1%) individuals with sporadic schwannomatosis. In all individuals with a germline mutation in SMARCB1 in whom tumour tissue was available, we detected a second hit with loss of SMARCB1. In addition, in all affected individuals with SMARCB1 mutations and available tumour tissue, we detected bi-allelic somatic inactivation of the NF2 gene. SMARCB1 mutations were associated with a higher number of spinal tumours in patients with a positive family history (p = 0.004).

Conclusion: In contrast to the recent report where no NF2 mutations were identified in a schwannomatosis family with SMARCB1 mutations, in our cohort, a four hit model with mutations in both SMARCB1 and NF2 define a subset of patients with schwannomatosis.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • Ethics approval: Approval for the study was provided by the local ethics committee.

  • Patient consent: Informed consent was obtained from the patients and families for publication of their details in this report.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd